{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:25:02Z","timestamp":1790191502612,"version":"4.1.0"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>It remains uncertain which chemotherapy sequence is more effective for locoregionally advanced nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of induction-concurrent with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>In this open-label, randomized, phase 3 clinical trial conducted at Sun Yat-sen University Cancer Center (China) from November 20, 2017, to March 19, 2021, patients aged 18 to 65 years with stage T1-4N2-3M0 and a pretreatment Epstein\u2013Barr virus DNA level of 1500 or more copies\/mL were enrolled. The data were analyzed from December 2024 to March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>The patients were randomly assigned to receive 3 cycles of paclitaxel-cisplatin-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy followed by 3 cycles of cisplatin-fluorouracil adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>The primary end point was 3-year progression-free survival, assessed locally by the investigator and defined as the time from random assignment to documented local or regional relapse, distant metastasis, or death of any cause, whichever occurred first.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 162 patients (median [IQR] age, 44 [34-53] years; 40 female individuals [24.7%]) were assigned to the induction-concurrent group and 162 (median [IQR] age, 45 [37-52] years; 36 female individuals [22.2%]) to the concurrent-adjuvant group. Regarding the data cutoff (October 8, 2024), the median (IQR) follow-up period was 60.4 (58.2-62.6) months. The 3-year progression-free survival rates were 73.5% (95% CI, 65.9%-79.6%) in the induction-concurrent group and 70.4% (95% CI, 62.7%-76.8%) in the concurrent-adjuvant group (stratified hazard ratio, 0.86; 95% CI, 0.58-1.27;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.45). The most common short-term grade 3 or worse adverse events were leukopenia (53 of 160 [33.1%] in the induction-concurrent group vs 47 of 142 [33.1%] in the concurrent-adjuvant group), neutropenia (52 [32.5%] vs 32 [22.5%], respectively), and mucositis (47 [29.4%] vs 42 [29.6%], respectively). The most common grade 3 or worse late adverse event was auditory or hearing loss (10 [6.3%] vs 12 [8.5%], respectively). Two patients in the induction-concurrent group died of treatment-related toxic effects. No treatment-related death occurred in the concurrent-adjuvant group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This randomized clinical trial found that induction-concurrent chemotherapy did not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma. Both treatment strategies were effective, and clinicians should discuss with the patients about the potential risks and benefits of the induction chemotherapy or adjuvant chemotherapy to provide the most appropriate treatment for patients with high-risk features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03306121?term=NCT03306121&amp;amp;amp;rank=1\">NCT03306121<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.1597","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T11:00:57Z","timestamp":1750244457000},"page":"864","source":"Crossref","is-referenced-by-count":11,"title":["Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma"],"prefix":"10.1001","volume":"11","author":[{"given":"Shan-Shan","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Lan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yi","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xiang","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Diagnosis and Therapy, Guangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi250025r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10192","key":"coi250025r2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma.","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"coi250025r3","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250025r4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","article-title":"Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.","volume":"97","author":"Chan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"coi250025r5","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1200\/JCO.2004.00.7542","article-title":"Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 trial by the Hong Kong Nasopharyngeal Cancer Study Group.","volume":"23","author":"Lee","year":"2005","journal-title":"J Clin Oncol"},{"issue":"27","key":"coi250025r6","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","article-title":"Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.","volume":"23","author":"Wee","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250025r7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.ijrobp.2007.12.028","article-title":"Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China.","volume":"71","author":"Chen","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"coi250025r8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2003.06.158","article-title":"Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.","volume":"21","author":"Lin","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250025r9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","article-title":"What is the best treatment of locally advanced nasopharyngeal carcinoma? an individual patient data network meta-analysis.","volume":"35","author":"Ribassin-Majed","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250025r11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"coi250025r12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial.","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250025r13","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","article-title":"Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi250025r14","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial.","volume":"8","author":"Miao","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10297","key":"coi250025r15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"coi250025r16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/annonc\/mdr116","article-title":"Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.","volume":"23","author":"Fountzilas","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"coi250025r17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.","volume":"27","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi250025r18","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma.","volume":"91","author":"Tan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"coi250025r19","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"coi250025r20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.","volume":"119","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"coi250025r21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma.","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"coi250025r22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cncr.29208","article-title":"Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.","volume":"121","author":"Lee","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"coi250025r23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis.","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol"},{"key":"coi250025r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100895","article-title":"Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA-IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial.","volume":"40","author":"Luo","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"coi250025r26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1186\/s12885-018-5192-x","article-title":"Liposomal paclitaxel versus docetaxel in induction chemotherapy using taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.","volume":"18","author":"Liu","year":"2018","journal-title":"BMC Cancer"},{"issue":"12","key":"coi250025r27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/14656566.2016.1204293","article-title":"A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation\/surgery.","volume":"17","author":"Wang","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"coi250025r28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"69","key":"coi250025r29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model.","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"7","key":"coi250025r30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models.","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"3","key":"coi250025r31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10549-021-06125-7","article-title":"Time-varying effects of FOXA1 on breast cancer prognosis.","volume":"187","author":"Chen","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"coi250025r32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2809","article-title":"Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review.","volume":"344","author":"Akl","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"coi250025r33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijrobp.2006.03.054","article-title":"Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and\/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.","volume":"66","author":"Lee","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"coi250025r34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.oraloncology.2019.08.001","article-title":"Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.","volume":"97","author":"Zhu","year":"2019","journal-title":"Oral Oncol"},{"issue":"34","key":"coi250025r35","doi-asserted-by":"publisher","first-page":"8636","DOI":"10.1200\/JCO.2004.00.1990","article-title":"Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.","volume":"23","author":"Hitt","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi250025r36","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/annonc\/mdf268","article-title":"Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial.","volume":"13","author":"Hitt","year":"2002","journal-title":"Ann Oncol"},{"issue":"11","key":"coi250025r37","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(16)30444-2","article-title":"Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?","volume":"17","author":"Spiotto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi250025r38","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials.","volume":"47","author":"Lee","year":"2011","journal-title":"Eur J Cancer"},{"issue":"7","key":"coi250025r39","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO.20.03237","article-title":"Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline.","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi250025r40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/annonc\/mdh308","article-title":"Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.","volume":"15","author":"Brockstein","year":"2004","journal-title":"Ann Oncol"},{"issue":"34","key":"coi250025r41","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"coi250025r42","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.19.00674","article-title":"Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial.","volume":"37","author":"da Costa","year":"2019","journal-title":"J Clin Oncol"},{"key":"coi250025r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104686","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.","volume":"105","author":"Tang","year":"2020","journal-title":"Oral Oncol"},{"issue":"45","key":"coi250025r44","doi-asserted-by":"publisher","first-page":"79953","DOI":"10.18632\/oncotarget.20389","article-title":"Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"coi250025r45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2016.12.009","article-title":"Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area.","volume":"73","author":"Liang","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"coi250025r46","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.oraloncology.2012.04.006","article-title":"A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.","volume":"48","author":"Huang","year":"2012","journal-title":"Oral Oncol"},{"issue":"4","key":"coi250025r47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2023.6552","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial.","volume":"10","author":"Dai","year":"2024","journal-title":"JAMA Oncol"},{"issue":"22","key":"coi250025r48","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial.","volume":"40","author":"Zhang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250025r49","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41467-023-35995-2","article-title":"Evolutionary route of nasopharyngeal carcinoma metastasis and its clinical significance.","volume":"14","author":"Lin","year":"2023","journal-title":"Nat Commun"},{"key":"coi250025r50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial.","author":"Liang","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"coi250025r51","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1002\/ONCO.13520","article-title":"Meta-analysis on induction chemotherapy in locally advanced nasopharyngeal carcinoma.","volume":"26","author":"Man\u00e9","year":"2021","journal-title":"Oncologist"},{"key":"coi250025r52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591205","article-title":"Effect of induction chemotherapy in nasopharyngeal carcinoma: an updated meta-analysis.","volume":"10","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"coi250025r10","unstructured":"David? G, Pfister? SS, Adelstein? D, Adkins? D, Brizel? DM. National Comprehensive Cancer Network clinical practice guidelines in oncology for head and neck cancers V.3.2019. Accessed September 23, 2019. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437"},{"key":"coi250025r24","unstructured":"David? G, Pfister? RIH, Shah? JP, Spencer? S, Hicks? WL. National Comprehensive Cancer Network clinical practice guidelines in oncology for head and neck cancers v.2.2024. Accessed December 16, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2835451\/jamaoncology_guo_2025_oi_250025_1755187162.07039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:00:37Z","timestamp":1755788437000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2835451"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.1597","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}